読み込み中
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
終値時点
$0.787
−$0.0361 · -4.39%
日中の時刻はETです。市場データは遅延する場合があります。
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
日中レンジ
現在 $0.787
52週レンジ
現在 $0.787
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
76
割安
センチメント
51
まちまち
リスク
73
高リスク
モメンタム
40
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
日中レンジ
現在 $0.787
52週レンジ
現在 $0.787
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1229.3万 USD | 2437.5万 USD | 2474.5万 USD | 2384.9万 USD | 4739万 USD |
| 売上原価 | 569.7万 USD | 1366.8万 USD | 1369.2万 USD | 1221万 USD | 2836.8万 USD |
| 粗利益 | 659.6万 USD | 1070.7万 USD | 1105.3万 USD | 1163.9万 USD | 1902.2万 USD |
| 研究開発 | 416.3万 USD | 378.5万 USD | 439.9万 USD | 772.7万 USD | 926.6万 USD |
| 販売・一般管理 | 2084.5万 USD | 3120.5万 USD | 2719.1万 USD | 3390.1万 USD | 3251.2万 USD |
| 営業費用 | 2500.8万 USD | 4635.8万 USD | 4157.9万 USD | 4682.8万 USD | 4205.4万 USD |
| 支払利息 | −38.7万 USD | 477.9万 USD | 579.6万 USD | 511.8万 USD | 532.4万 USD |
| 減価償却費と償却費 | 278.5万 USD | 108.3万 USD | 374.8万 USD | 373.3万 USD | 373万 USD |
| 営業利益 | −1841.2万 USD | −3565.1万 USD | −3052.6万 USD | −3518.9万 USD | −2303.2万 USD |
| 純利益 | 5338万 USD | −5394.9万 USD | −3765.6万 USD | −3289.7万 USD | −2483.2万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$8.88
上昇余地（1028.34%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
